Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1997-10-31
2000-10-31
Chan, Christina Y.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
5303873, 5303881, 5303913, 4241331, 4241341, 4241416, 435810, A61K 39395, C07K 1640
Patent
active
061404748
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to hybridomas producing a monoclonal antibody reactive to human cholesterol ester transfer protein(CETP), a monoclonal antibody and its fragment reactive to human CETP, an immobilized monoclonal antibody and immobilized antibody fragment, a labeled monoclonal antibody and labeled antibody fragment, a kit for detection, assay, separation or purification of human CETP, a method for detection, assay, separation and purification of human CETP and a pharmaceutical composition containing said monoclonal antibody or said antibody fragment.
BACKGROUND OF THE INVENTION
There are three types of cholesterol, free type, long chain fatty acid type and ester type, in all the tissues and blood plasma in organisms. The former two play important roles in the composition of cell membranes. The latter is physiologically inactive and exists mainly in a storage form. Cholesterols in a body are derived from ingestion in the small intestine or from biosynthesis in various tissues, especially in the liver. Most cholesterols are derived from biosynthesis in the liver.
Free cholesterol biosynthesized and secreted from the liver is incorporated in very low density lipoprotein (VLDL). Then, by the actions of lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL), it is metabolized to low density lipoprotein (LDL) through intermediate density lipoprotein (IDL). By the incorporation of LDL into LDL receptors of peripheral cells, free cholesterol is supplied to cells.
There is a pathway from the peripheral cells to the liver called the cholesterol reverse transfer system, which goes in reverse of the way from liver to peripheral cells as mentioned above. Surplus free cholesterol supplied in the peripheral cells from the liver is drawn by high density lipoprotein (HDL) in blood. Then, by the action of lecithin cholesterol acyl transferase (LCAT), it is converted to cholesterol ester and is stored in high density lipoprotein (HDL) in blood. By the action of cholesterol ester transfer protein(CETP), the cholesterol ester stored in HDL is transferred to VLDL, IDL or LDL in blood. By the incorporation of VLDL, IDL or LDL cholesterol ester received through LDL receptors in the liver, cholesterol is indirectly transferred to the liver.
Recently, the reverse cholesterol transfer system has drawn much attention as a mechanism for preventing the peripheral cells from accumulating cholesterol and thereby preventing atherosclerosis. In fact, as for HDL which plays an important role in the reverse cholesterol transfer system, many epidemiological surveys show that decrease of cholesterol ester in blood HDL is one of the risk factors of coronary artery disorders. It is now well recognized that HDL is a lipoprotein having anti-arteriosclerosis action.
In addition to the importance of blood HDL, it became recognized that CETP is also important because it mediates transfer of cholesterol ester in HDL into blood LDL. Therefore, it became an urgent matter to elucidate the relationship between CETP and various diseases such as CETP deficiency, hyperlipidemia, hyperalphalipoproteinemia, hypercholesterolemia, hypolipidemia, arteriosclerosis, diabetes and nephrotic syndrome.
For instance, it is experimentally demonstrated that several times higher CETP are secreted in blood of the patients with hyperlipidemia compared to those of healthy volunteers. The following findings have been made in relation to arteriosclerosis. When CETP activity is low, arteriosclerosis is not easily induced and the level of HDL cholesterol is high. In contrast, when CETP activity is high, arteriosclerosis is easily induced and the level of HDL cholesterol is low. Such relationships have been experimentally demonstrated (Current Therapy, vol. 7, 9:36-45(1989)).
In order to elucidate the relationship between various diseases and CETP, assay methods for CETP in body fluids such as blood plasma from a healthy person or patient having the above various diseases, especially immunoassay methods such as radio-immunoassay (RIA
REFERENCES:
patent: 5530101 (1996-06-01), Queen
Clark et al. J. Lipid Research 36:878, 1995.
Mezdour et al. Clin. Chem. 40:593, 1994.
Wang et al. J. Biol. Chem. 267:17487, 1992.
Hesler et al. J. Biolchem 2631:5020, 1988.
Agellon et al. J. Biol. Chem 266:10796, 1991.
Swenson et al. J. Biol. Chem. 264:14318, 1989.
Whitlock, Mary E. et al., J. Clin. Invest., vol. 84, (Jul. 1989), 129-137.
Marcel, Yves L. et al, J. Clin. Invest., vol. 85, (Jan. 1990), 10-17.
Kamada Masafumi
Okamoto Hiroshi
Tamatani Takuya
Chan Christina Y.
Japan Tobacco Inc.
Lubet Martha
LandOfFree
Monoclonal antibody reactive with human-origin CETP and method o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody reactive with human-origin CETP and method o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody reactive with human-origin CETP and method o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2053421